Nonalcoholic Steatohepatitis and Noncirrhotic Hepatocellular Carcinoma
Seminars in Liver Disease, 03/13/2012Torres DM et al.
The review focuses on nonalcoholic fatty liver disease (NAFLD) carcinoma (HCC) in noncirrhotic NASH with an emphasis on clinical presentation, pathogenesis, and implications for screening.
Nonalcoholic fatty liver disease (NAFLD) is easily the most common cause of chronic liver disease in the United States (U.S.) as the hepatic manifestation of the metabolic syndrome.
Although only 5 to 20% of patients with NAFLD are generally considered to meet criteria for nonalcoholic steatohepatitis (NASH), with its inherent risk for progression to cirrhosis, this still represents an alarmingly large number of individuals.
The exponentially growing rates of hepatocellular carcinoma (HCC) in the U.S. may be partially attributable to increased numbers of NASH cirrhotics, although recent evidence has suggested that NAFLD may directly promote hepatic carcinogenesis independent of cirrhosis.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.